Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 12/20 | 0.64 |
| ▸ | TMPRSS4 | Q9NRS4 | 9/20 | 0.64 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.64 |
| ▸ | P2RX4 | Q99571 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | IKBKB | O14920 | 1/20 | 0.64 |
| ▸ | CHUK | O15111 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | MYLK | Q15746 | 1/20 | 0.64 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.64 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | XPO1 | O14980 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511638 | 1.00 | P2RX1 (0.64) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| Potassium Ion SCHEMBL29511655 | 0.99 | P2RX1 (0.62) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL28359926 | 0.93 | P2RX1 (0.61) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL28359764 | 0.93 | P2RX1 (0.61) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL16702757 | 0.90 | P2RX1 (0.67) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL6102085 | 0.89 | P2RX1 (0.65) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL28359923 | 0.88 | P2RX1 (0.64) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL19862002 | 0.87 | P2RX1 (0.62) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL19862000 | 0.86 | P2RX1 (0.61) | P2RX1TMPRSS4P2RX7P2RX4MEN1 | |
| SCHEMBL23789521 | 0.85 | TMPRSS4 (0.60) | P2RX1TMPRSS4P2RX7P2RX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166673-A1 | CRYSTALS | AEROMICS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-11801254-B2 | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | AEROMICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11725018-B2 | Crystals | AEROMICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220204536-A1 | CRYSTALS | AEROMICS, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| CN-110790787-B | Water-soluble prodrug, preparation method thereof and application thereof as medicine | 广东药科大学 | 2022-06-14 | — | — | CN | disclosed |
| US-20220143048-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11117909-B2 | Crystals | AEROMICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210275549-A1 | NOVEL FORMULATIONS | AEROMICS, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-11071744-B2 | Prodrug salts | AEROMICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| CN-112402434-A | New formula | 埃罗米克斯公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3454846-A1 | CRYSTALS | Aeromics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180169118-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9827253-B2 | Prodrug salts | AEROMICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2017197371-A1 | CRYSTALS | AEROMICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20160279155-A1 | NOVEL FORMULATIONS | AEROMICS, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160264604-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| EP-3065729-A2 | NOVEL FORMULATIONS | Aeromics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3065727-A1 | NOVEL PRODRUG SALTS | Aeromics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069961-A1 | NOVEL PRODRUG SALTS | AEROMICS, LLC (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069956-A2 | NOVEL FORMULATIONS | AEROMICS, LLC (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801254-B2 | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | PLCG2, DCTPP1, PLCG1 | P2RX1 790/4885TMPRSS4 1479/4885P2RX7 528/4885 |
| US-20220204536-A1 | CRYSTALS | MTAP, PLCG2, PLCG1 | P2RX1 2559/4885TMPRSS4 2690/4885P2RX7 2777/4885 |
| US-20210275549-A1 | NOVEL FORMULATIONS | DCPS, PRCP, DCTPP1 | P2RX1 1115/4885TMPRSS4 228/4885P2RX7 778/4885 |
| US-20180169118-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | P2RX1 543/4885TMPRSS4 1033/4885P2RX7 442/4885 |
| US-20160264604-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | P2RX1 543/4885TMPRSS4 1033/4885P2RX7 442/4885 |
| US-11725018-B2 | Crystals | MTAP, PLCG2, PLCG1 | P2RX1 2559/4885TMPRSS4 2690/4885P2RX7 2777/4885 |
| US-20160279155-A1 | NOVEL FORMULATIONS | AQP1, AQP4, AQP3 | P2RX1 314/4885TMPRSS4 1948/4885P2RX7 226/4885 |
| US-20220143048-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | P2RX1 543/4885TMPRSS4 1033/4885P2RX7 442/4885 |
| US-20240166673-A1 | CRYSTALS | MTAP, PLCG2, PLCG1 | P2RX1 2559/4885TMPRSS4 2690/4885P2RX7 2777/4885 |
| US-11117909-B2 | Crystals | MTAP, PLCG2, PLCG1 | P2RX1 2559/4885TMPRSS4 2690/4885P2RX7 2777/4885 |
| US-11071744-B2 | Prodrug salts | AQP4, AQP1, AQP3 | P2RX1 556/4885TMPRSS4 1144/4885P2RX7 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.